Kornimate/medical-research-clean huggingface dataset:
digital occlusal analysis and enamel wear assessment in temporomandibular disorder patients treated with fully digital versus conventional stabilization splints

Conditions: TMD; Temporomandibular Disorders (TMD)

Summary: this randomized controlled research aimed to analyse the occlusion and assist the enamel wear before and after using of the stabilization splints produced by the conventional methods with the fully digitally fabricated stabilization splints. research question: will the fully digital stabilization splint offer significantly better occlusal equilibration and enamel wear compared to the conventional stabilization splint? the primary outcome will be digital occlusal analysis, and secondary outcome will be enamel wear assessment

this randomized controlled clinical trial investigates the effectiveness of fully digitally fabricated stabilization splints (fd-ss) versus conventionally manufactured stabilization splints (c-ss) in patients with temporomandibular disorders (tmd). the study focuses on two primary outcomes: digital occlusal analysis and enamel wear assessment over a 6-month period. participants are tmd patients aged 18-40 with stable jaw relations and intact dentition, randomly assigned (1:1) to the fd-ss or c-ss group. digital occlusal analysis is performed using occlusense technology, which captures bite force distribution and contact points dynamically and statically. enamel wear is assessed quantitatively using an intraoral scanner paired with geomagic control x 3d software for surface matching analysis. baseline and follow-up stl datasets are compared to quantify volumetric enamel loss with micrometer precision. in the fd-ss group, fully digital stabilization splints are fabricated using a digital workflow that includes intraoral scanning, jaw tracking with zebris jma devices, and cad/cam design in exocad software. splints are manufactured using 3d printing technology. in the c-ss group, conventional splints are fabricated using alginate impressions, plaster casts, and manual adjustments on a semi-adjustable articulator. this study aims to advance the understanding of digital technologies in managing tmd, providing evidence for their efficacy in improving occlusal balance and minimizing enamel wear.

Eligibility criteria:
inclusion criteria: 1. 18-40 years old 2. complete dentition 3. intact tooth 4. no occlusal disorder 5. stable jaw relation 6. no ongoing dental therapy, such as orthodontic or prosthodontics treatment. exclusion criteria: 1. pregnant/lactating women 2. temporomandibular joint lesions found on clinical palpation or medical imaging examination 3. dentoalveolar pathology or ongoing treatment related to tmd 4. jaw opening less than 3 fingers 5. patients with occlusal dysfunctions 6. patients with severe or moderate periodontitis. 7. unable to undergo examination or treatment due to the presence of a psychological or mental disorder. 8. severe jaw functional limitations. 9. removable dentures or partially dentate patients 10. trauma of recent date towards face, head or neck

Keywords: temporomandibular disorder, tmd, digital occlusal analysis enamel wear assessment stabilization splints
safety and efficacy of entospletinib with vincristine and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia (all)

Conditions: Acute Lymphoblastic Leukemia

Summary: the primary objective of this study is to evaluate the safety of entospletinib in combination with vincristine (vcr), and dexamethasone (dex) in adults with previously treated relapsed or refractory b-cell lineage acute lymphoblastic leukemia (all). this is a dose escalation study in which after 2 induction cycles participants may be put on maintenance for up to 36 cycles if they have obtained clinical benefit from the treatment.


Eligibility criteria:
key inclusion criteria: * adults with all in need of treatment key exclusion criteria: * diagnosis of burkitt's leukemia, or lymphoid blast crisis of chronic myelogenous leukemia (cml) * history of myelodysplastic syndrome or solid organ transplantation * prior allogeneic bone marrow progenitor cell transplant within 100 days or on active immunosuppression for graft versus host disease (gvhd) treatment or prophylaxis within 28 days prior to enrollment note: other protocol defined inclusion/ exclusion criteria may apply.

Keywords: syk inhibitor blood malignancy leukemia
gemcitabine plus erlotinib versus erlotinib plus gemcitabine plus oxaliplatin, in pancreatic cancer

Conditions: Pancreatic Cancer

Summary: this randomized phase ii trial will compare the efficacy and toxicity of gemcitabine plus erlotinib versus gemcitabine plus erlotinib plus oxaliplatin in patients with pancreatic cancer.


Eligibility criteria:
inclusion criteria: * histologically confirmed pancreatic cancer. * measurable disease. * absence of ascites or obstructive jaundice. * ecog performance status 0-2. * adequate liver kidney and bone marrow function. * written informed consent. exclusion criteria: * chronic diarrheic syndrome. * uncontrolled brain metastases after radiation. * liver infiltration over 50%. * peripheral neuropathy ≥ 2. * no second primary malignancy within the past 5 years, except non-melanomas skin cancer or in situ carcinoma of the cervix. * no active uncontrolled infection. * active cardiac disease : unstable angina or onset of angina within last 3 months, myocardial infarction within 6 months, congestive heart failure \> class ii, cardiac ventricular arrhythmias requiring anti-arrhythmic therapy. * women who are pregnant or lactating.
effectiveness of tiotropium + olodaterol versus inhaled corticosteroids (ics) + long-acting β2-agonists (laba) among copd patients in taiwan

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: the real world study aims to assess effectiveness and safety profile between tiotropium/olodaterol (tio/olo) and inhaled corticosteroids(ics) / long-acting β2-agonists (laba) in patients with chronic obstructive pulmonary disease (copd) in taiwan. the data used in this study will come from the taiwan national health insurance (nhi) claims data between 2014 and 2019.


Eligibility criteria:
inclusion criteria: 1. at least one prescriptions for tiotropium/olodaterol (tio/olo) combined inhaler or long-acting ß2 agonist / inhaled corticosteroids (laba/ics) combined inhaler between 1st january 2014 and 31st december 2019. 1. the first dispensing of either tio/olo or laba/ics combined inhaler will be defined as the index date; 2. for the main analyses, only fixed dose combination (fdc) inhalers will be included. 2. aged ≥ 40 years on the index date (in a sensitivity analysis we will only include patients aged ≥ 55 years on the index date); 3. at least one diagnosis of chronic obstructive pulmonary disease (copd) at any time prior to or on the index date; 4. at least one year of continuous medical and health insurance plan prior to the index date will be required to allow for a look-back period for the covariates and identification of new use of the study drugs; 5. at least one record in the health insurance system database exclusion criteria: 1. any use of tio/olo, ics/laba, or ics/laba/ long-acting muscarinic antagonists (lama) in free or fixed form for one year prior to the index date; 2. individuals with asthma, allergic rhinitis, lung cancer, interstitial lung disease, or lung transplant identified at any time prior to the index date (in a sensitivity analysis we will include patients with asthma);
study on clinical program optimization of inactive hepatitis b surface antigen (hbsag) carriers (ihcs)

Conditions: Chronic Hepatitis B

Summary: a multicenter, randomized controlled trial design was used to select patients with chronic hepatitis b in the immune control phase (i.e. hbsag positive, hbeag negative, normal alt and hbsag≤1000iu/ml, hbv dna≤2000iu/ml) to enter this study, and to compare the feasibility, effectiveness and safety treated with pegylated interferon α2b continuous therapy or pulse therapy in immune-controlled chronic hepatitis b patients.

patients:chronic hepatitis b in the immune control phase (i.e. hbsag positive, hbeag negative, normal alt and hbsag≤1000iu/ml, hbv dna≤2000iu/ml). the study patients were divided into two groups.group a (peg ifn α- 2b continuous group): peg ifn was injected subcutaneously once a week from the first day of baseline α- 2b 180 μg. the total course of treatment should not exceed 96 weeks.group b (peg ifn α- 2b pulse group): from the first day of baseline, peg ifn was injected subcutaneously α- 2b 180 μg. every 8 weeks of injection, stop for 4 weeks, and conduct it periodically.two groups at baseline, 4 weeks, 8 weeks, 12 weeks, 24 weeks, 36 weeks, 48 weeks, 60 weeks, 72weeks, 84 weeks, 96 weeks and the 12th and 24th weeks after drug withdrawal, and corresponding examinations were carried out at each follow-up.check and record adverse events and concomitant medication in detail, and evaluate the compliance of subjects; blood samples were retained and transported to the laboratory for hbv at baseline, 24 weeks, 48weeks, 72, 96, and 12 and 24 after drug withdrawal.dna quantification and detection of hepatitis b virus markers.the efficacy and safety were evaluated after the study.

Eligibility criteria:
inclusion criteria: * age 18 to 65 years, both male and female (including 18 and 65 years old); * hbv dna≤2000 iu/ml and hbeag negative; * hbsag positive for more than 6 months, and hbsag≤1000 iu/ml; * alt≤uln at screening (discontinue liver-protecting enzyme-lowering drugs for at least 2 weeks); * a negative urine or serum pregnancy test (for women of childbearing age) within 24 hours before the first dose; * b-ultrasound or fibroscan suggest no liver cirrhosis; * willing to accept treatment and sign informed consent. exclusion criteria: * participants with other hepatotropic viruses or human immunodeficiency virus co-infection; * other chronic non-viral liver diseases or decompensated liver diseases; * tumours; * drug abuse; * severe psychiatric disease; * uncontrolled thyroid disease or diabetes; * pregnancy or lactation.

Keywords: inactive hepatitis b virus carriers pegylated interferon α2b continuous treatment, pulse treatment
common bile duct stones - natural history and interventions

Conditions: Common Bile Duct Stone

Summary: the aims of this study were to 1. investigate what measures were taken when common bile duct stones (cbds) were found intraoperatively in sweden during the period may 2005 to december 2009 by using data from this population-based nationwide registry, and 2. analyze the outcome in terms of complications and success rates of bile duct clearance in relation to various stone sizes and interventions used. in order to further characterize the natural course of cbds of various sizes, particular interest was focused on patients with positive findings where no peroperative measures to clear the bile ducts were taken or planned postoperatively.


Eligibility criteria:
inclusion criteria: * common bile duct stones exclusion criteria: * none
extension study of herombopag for pediatric patients with chronic immune thrombocytopenia

Conditions: Immune Thrombocytopenia

Summary: the main purpose of this extended study is to enable subjects who are currently receiving the partb experimental drug in the hr-tpo-itp-iii-ped clinical trial .to continue receiving the experimental drug after the completion of the clinical trial if they benefit from the treatment at the end of the clinical trial.until the study physician determines that the subject has failed treatment or that the subject can no longer benefit from treatment or extends the study treatment for 6 months.in addition, the secondary purpose of this extended study was to observe the long-term efficacy and safety of tripodal in children and adolescents.


Eligibility criteria:
inclusion criteria: 1. subjects who have completed partb of hr-tpo-itp-iii-ped clinical trial and have achieved platelet response. 2. subjects who have signed the informed consent for the extended study. 3. subjects with potential fertility（e.g. women who have menarche or men who have sperm loss) should agree to use effective contraception during their participation in the extended study and within 28 days after their last dose. 4. subjects who have completed end-of-treatment visits in the original study. exclusion criteria: 1. any unstable condition or condition that may compromise the safety of the subject. 2. patients with new myelofibrosis were examined in the original clinical trial exit group. 3. the original clinical trial cohort examined evidence of new cataract or existing cataract progression, and the study considered it unsuitable to enroll in this extension. 4. patients with uncontrolled bleeding after standard treatment. 5. any previous occurrence of arterial or venous thrombosis (transient ischemic attack,myocardial infarction ,deep venous thrombus, or pulmonary embolism ),or clinical symptoms and history suggest thrombus susceptibility. 6. any other circumstances that the investigator considers likely to cause the subject to be unable to complete the study or to present a significant risk to the subject.
prevalence of stress urinary incontinence in obese versus non-obese nulligravid women

Conditions: Stress Urinary Incontinence

Summary: urinary incontinence (ui) is more common than any other chronic disease. stress urinary incontinence (sui), among the various forms of urinary incontinence, is the most prevalent (50%) type of this condition. female urinary continence is maintained through an integrated function of pelvic floor muscles (pfms), fascial structures, nerves, supporting ligaments, and the vagina. in women with sui, the postural activity of the pfms is delayed, and the balance ability is decreased. many women, by learning the correct timing of a pelvic floor contraction during a cough, are able to eliminate consequent sui. timing is an important function of motor coordination and could be affected by proprioception. we aim to assess stress urinary incontinence in obese and non-obese nulligravid females.


Eligibility criteria:
inclusion criteria: * women aged between18 and 45 years. * non obese females with bmi \<25kg/m2. * obese females with bmi ≥30kg/m2. * nulligravid females. exclusion criteria: * multiparous females * patients with active urinary tract infection. * patients with respiratory or neurological diseases. * patients with communication problems, cognitive disorders \& mental disturbance. * current treatment with drugs (benzodiazepines, diuretics) * patients who underwent any previous abdominal or pelvic surgery.
transcutaneous levator recession for non-thyroid lid retraction

Conditions: Eye Diseases

Summary: this work aims to describe and assess the efficacy of transcutaneous levator palpebrea superioris muscle recession as a surgical procedure for treatment of upper lid retraction of various causes other than thyroid eye disease


Eligibility criteria:
inclusion criteria: * patients suffering from upper eyelid retraction of various causes other than thyroid eye disease exclusion criteria: * patients refused to participate in the study, patients with systemic diseases causing lid retraction (such as guillain-barré syndrome), pseudo retractions, contralateral ptosis, local skin condition (as scar adherence), medication (such as sympathomimetic drugs, lithium, and steroid), neurological conditions (such as dorsal midbrain syndrome and hydrocephalus) and thyroid related lid retraction
effect of integrated care involving peripheral functional magnetic stimulation for sarcopenia

Conditions: Sarcopenia

Summary: the goal of this clinical randomized trial is to test whether an integrated care involving peripheral functional magnetic stimulation and nutritional supplement is beneficial in population with age-related sarcopenia, as compared to usual care.

we will recruit participants with sarcopenia or possible sarcopenia. the participants will be divided into 2 groups. one group, the "integrated care" group, will receive both the peripheral functional magnetic stimulation to both the upper and lower limbs and nutritional supplement for consecutive 8 weeks. the other group, the "usual care" group, will receive an educational digital versatile disc (dvd) and a handbook for exercise suggestions on sarcopenia. we will compare before and after the intervention about the body composition, handgrip strength, 5-time chair stand test, 6-meter walk, and blood test for c-reactive protein and other cytokines related to sarcopenia. the participant's nutritional condition, activity level, life quality will also be analyzed via questionnaires before and after the intervention.

Eligibility criteria:
inclusion criteria: * age from 65 to 90 * can walk independently for over 15 minutes * diagnosed with possible sarcopenia or sarcopenia (by asian working group for sarcopenia: 2019 consensus update onsarcopenia diagnosis and treatment) exclusion criteria: * cognitive impairment * history of cerebrovascular disease * deep vein thrombosis * malignancy under treatment * coagulopathy * serious orthopedic condition over limbs * inability to walk independently without assistive device * any other conditions not suggested to performance exercise * medical implants (e.g. pacemaker, defibrillator, deep brain nerve stimulation, infusion pump, etc.)

Keywords: sarcopenia functional magnetic stimulation
improving outcomes and quality of life after cabg

Conditions: Coronary Artery Bypass Graft Surgery Patients

Summary: the principal objective to this randomized trial is to compare the efficacy of two strategies of intra-operative hemodynamic management during cardiopulmonary bypass among patients undergoing primary elective coronary artery bypass graft (cabg) surgery in preventing peri-operative cardiac, cognitive and neurologic morbidity and mortality and post-operative deterioration in the patient's quality of life as measured by the seven domains of sf-36 health survey (bodily pain, health perceptions, energy, and mental, physical, social and role function).

in one group, mean arterial pressure (map) was 65 mmhg. in the other, the map target was determined by the patients usual preoperative map. thus, the trial will evaluate whether tailoring the map target for the period of cardiopulmonary bypass to within 10 mmhg of the patients usual map, but \< 90 mmhg (and thus achieving pressures during bypass within the patients usual autoregulatory range) reduces major neurologic and cardiac morbidity and mortality, as well as cognitive complications, thereby improving post-operative quality of life.

Eligibility criteria:
inclusion criteria: * all patients undergoing primary elective/urgent coronary artery bypass graft (cabg) surgery. exclusion criteria: * patients who elect not to participate in the study * patients undergoing valve replacement or other cardiovascular surgical procedures * patients who are not fluent in english * patient who cannot provide informed written consent

Keywords: cardiopulmonary bypass coronary artery disease cardiac morbidity neurologic morbidity neurocognitive function autoregulation
child health improvement through computer automation of constipation management in primary care

Conditions: Constipation; Encopresis

Summary: this project seeks to expand an existing computerized decision support system used in pediatric primary care. the expanded system will add a module that helps clinicians recognize constipated children and then provides evidence-based reminders for constipation management, as well as automates patient educational materials. the current system is deployed across multiple sites, and the constipation module will be randomized to deployment in different sites. the difference in constipation management and patient outcomes will then be compared between sites receiving the intervention and sites not receiving the intervention over a 12 month period.


Eligibility criteria:
inclusion criteria: * patients presenting to one of 5 primary care clinics in the eskenazi health system in indianapolis, in. * patients given a pre-screener form as part of the existing chica decision support system. * age between 2 years and 12 years, inclusive. exclusion criteria: * none.
pre-dinner vs. post-dinner exercise on glycemic control

Conditions: Type 2 Diabetes

Summary: with many medications we prescribe them relative to time of day or a meal. this study established if pre dinner vs post dinner exercise was more effective at altering post dinner glucose and triglyceride levels vs no exercise at all.

all participants completed three trials in a random order in which they consumed a standardized dinner meal with 1) no re (nore), 2) pre-dinner re (re→m), and 3) post-dinner re beginning 45 min after dinner (m→re). diet was standardized during the day of testing. participants reported to the lab for testing sometime between 3 - 5:30 p.m. and upon arrival a venous catheter was inserted into a forearm vein. frequent blood sampling, indirect calorimetry measurements, and subjective well-being measurements ensued for \~5.75 h while the participants were in the lab.

Eligibility criteria:
inclusion criteria: * obese ( body mass index 30-45 kg/m2) * physician diagnosed with type 2 diabetes receiving standard medical care * non-smokers * pregnancy * lactating mothers exclusion criteria: * insulin * surgical weight loss * orthopedic limitations to exercise * weight loss in the previous 3 months

Keywords: gip glp-1 exercise timing resistance exercise glucose concentrations
low contrast agent and radiation dose protocol for liver ct in patients with hcc

Conditions: Hepatocellular Carcinoma

Summary: the purpose of this study is to investigate the image quality and clinical feasibility of double low-dose liver computed tomography using a deep-learning-based iodine contrast boosting algorithm in participants at high risk for hepatocellular carcinoma.

the purpose of this study is to investigate the image quality (cnr, subjective inage quality, vessel and lesion conspicuity) and clinical feasibility (rate of lesion detection) of double low-dose liver computed tomography using a deep-learning-based iodine contrast boosting algorithm in participants at high risk for hepatocellular carcinoma.

Eligibility criteria:
inclusion criteria: * liver cirrhosis * tumor marker (afp, pivka) elevation * nodular lesion on usg * received rfa for hcc exclusion criteria: * hypersensitivity at iodine * gfr under 30 * bmi over 30 * nursing or pregnant women * enrolled the other study

Keywords: ct